Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and is metabolised by dimethylarginine dimethylaminohydrolase (DDAH).
INTRODUCTION
All three isoforms of nitric oxide synthase (NOS) are inhibited by the endogenous methylated arginines N G N G -dimethylarginine (ADMA) and L-N Gmonomethylarginine (L-NMMA) [1;2] . These methylarginines are synthesised when arginine residues in proteins are methylated by the action of protein arginine methyltransferases (PRMT) [3] . As the proteins are hydrolysed, free ADMA and L-NMMA are released into the cytosol and may compete with L-arginine, the substrate for NOSs, and lead to inhibition of nitric oxide (NO) generation. The major route of clearance of ADMA and L-NMMA is hydrolysis to citrulline and methylamines by dimethylarginine dimethylaminohydrolases (DDAHs) [4;5] . Whilst it is clear that increased plasma concentrations of ADMA correlate with various cardiovascular pathologies [6] [7] [8] and that pharmacological administration of ADMA or L-NMMA produces substantial cardiovascular effects [9] , there is less known about the effects of the endogenous ADMA/DDAH pathway on the behaviour of cells that generate ADMA. The aim of the present study was to test the hypothesis that manipulation of DDAH activity or expression would alter ADMA levels and affect cell phenotype.
The focus was on the ability of cells to form "tube-like" structures when grown in Matrigel.
METHODS
Studies were undertaken in 3 cell types -ECV304 cells, human umbilical vein endothelial cells (HUVEC) and the murine endothelial cell line sEnd.1. Studies to explore the effects of DDAH over-expression were undertaken using ECV304 cells because these cells transfect readily and migrate to form linear "tube-like" structures in Matrigel [10;11] . To determine whether the effects seen with ECV304 cells might be relevant to endothelial cells we studied human umbilical vein endothelial cells (HUVEC) and a murine endothelial cell line sEnd.1. We also used a sEnd.1 cell line that over-expresses DDAH-II that we have described previously [12] .
Cell culture
Unless otherwise stated cell culture reagents were purchased from Invitrogen.
ECV304 cells were grown in M199 medium (Sigma) supplemented with 10 % (v/v) foetal bovine serum, penicillin 1000U/ml, streptomycin 1000 µg/ml and L-glutamine 2 mM as previously described [13] . HUVEC were cultured as described previously [4] and used prior to passage 6. sEnd.1 cells were cultured as described previously [12] .
Construction of expression plasmids
Human kidney poly(A)+ RNA was reverse transcribed using an oligo(dT) primer and 
Transfection of ECV304 cells
24 h prior to transfection the cells were seeded at 80 % confluence onto a 9 mm petri dish. Transfection was carried out using TransFast transfection reagent (Promega) according to the manufacturer's instructions. 48 h after transfection, cells containing the expression plasmids were selected by incorporating 800 µg/ml G418 sulphate (Sigma) into the cell culture medium. Approximately 10 days after addition of G418 sulphate, individual colonies of resistant cells were transferred to a 24-well plate containing M199 media supplemented with 400 µg/ml G418 sulphate. Cells overexpressing DDAH II mRNA were screened by northern blotting, using a DDAH II cDNA probe.
Northern blotting
Total RNA was extracted from cells using TRIzol reagent (Invitrogen) and probed for β-actin and DDAH II as previously described [14] . A human vascular endothelial growth factor (VEGF1) cDNA probe was generated by PCR. All mRNA levels described were corrected against β-actin mRNA levels. Flk-1 expression was determined by binding to 3' primer (TCTGCAGTGCACCACAAAGACAC), designed from human flk-1 sequence (AF035121), and phosphorylated by T4 polynucleotide kinase (Promega). Transcripts that hybridised to the probes were detected using a phosphoimager (Fugi BAS 1000).
Immunoblotting
Aliquots of cell lysates were resolved by 12% SDS-PAGE, DDAH II was found to migrate at 38-40 kDa and was detected using an antibody raised in rabbit against a peptide from DDAH II 241-255 as previously described [15] .
Cell growth assay
Cells were seeded onto a 96-well microtiter plate at a density of 500 cells per well and grown in ECV304 medium. Cell growth was assayed (in triplicate) over a 4-day period using the cell titer 96 Aqueous One solution Cell Proliferation Assay (Promega).
Matrigel assay
ECV304 or HUVEC were overlaid onto 100 µl Matrigel TM (Becton Dickinson) in 24-well plates. Digital photographs of the cells were collected using an inverted microscope (Axiovert) coupled to an Improvision Apple Macintosh system, each experiment was performed in duplicate (n refers to number of duplicates) and 5 random pictures were taken of each well at a magnification of x 10. The area of linear "tube" formation in each picture was analysed, by an individual who was blinded to the cell types and treatments, using the Openlab (Improvision) software package and all "tubes" across a fixed field of magnification (x 10) were measured [11] . Where cells were treated with oxindole or VEGF, data were expressed as % of control (untreated ECV304 cells).
ADMA measurements
60 % confluent cells were grown in fresh culture medium for 24h. Methylated arginines in the conditioned medium were quantitated by HPLC as previously described [6] .
DDAH activity assay
Cells were grown to confluence in 150 cm 2 flasks, cells were scraped and lysed for 20 min at 4 °C in sodium phosphate pH 6.6 (10 mM) buffer containing 0.1 % Triton X, cleared by centrifugation and assayed for DDAH activity as previously described [4] .
Statistics
Results were compared using students unpaired t-test. Values are given as means ± SEM where n=3 in separate experiments unless otherwise stated. (Fig 1C; p<0.05 ).
RESULTS AND DISCUSSION

Characterization of DDAH II over-expressing ECV304 cells
Changes in DDAH activity affected the concentration of ADMA secreted by cells into culture media over a 24h period, such that this fell from 6.31 ± 0.21 µg/ml (22.9 ± 0.8 µM) in control ECV304 cells to 5.10 ± 0.07 µg/ml (18.6 ± 0.3 µM) in the DDAH II over-expressing lines (Fig 1D; P<0 .01). Levels of SDMA, which is not a DDAH substrate, were unchanged between the two cell lines. Consequently, the ratio of ADMA: SDMA was 3.23 ± 0.1 and 2.73 ± 0.15 (p=0.024) for ECV304 and the overexpressing cells respectively (n=5). These results confirm that DDAH activity is a Although altered expression of DDAH clearly affected cell phenotype and behaviour (see below) we were unable to determine directly whether this was due to changes in NO generation. ECV304 cells are human in origin and produce NO that is at the limit of levels of detection. Consequently changes were small, even when cells were stimulated with calcium ionophore. It therefore remains possible that the effects of DDAH over-expression are independent of NO. This intriguing possibility or the possibility of compartmentalised changes in NO should be addressed in future studies.
DDAH II over-expression does not influence cell growth
The growth of cells was unaffected by DDAH over-expression. When grown under standard conditions no differences in cell growth were observed over a 4-day period between the untransfected cells and a DDAH over-expressing cell line (Fig 1E) .
DDAH over-expressing cells grown in culture flasks exhibited identical morphology to ECV304 cells and the cells transfected with the reverse orientated construct.
DDAH II over-expression enhances tube formation
Growth of ECV304 cells on Matrigel resulted in cell migration and elongation to form "tube-like" structures as described previously [10;16] . Cell lines which overexpressed DDAH II (Fig 2A) had greater tube formation than either untransfected ECV304 cells or cells transfected with a reverse orientated DDAH construct (ASD2B & ASD2C) (Fig 2B) . This effect is unlikely to be due to an artefact of clonal selection since it was reproduced in two independently derived over-expressing lines (D2X7 & D2X10). The area of the "tubes" after 48 h in DDAH over-expressing cells was 233.5 ± 48.0 % (D2X7) and 205.1 ± 30.5 (D2X10) compared to control cells (Fig 2B; for both cell lines p<0.005, n=4). There was no significant difference in DDAH activity or tube formation between the untransfected cells and those transfected with a reverse orientated DDAH construct.
Effect of the DDAH inhibitor on tube formation.
HUVEC also form "tube-like" structures on Matrigel similar to those produced by This concentration of 4124W inhibits DDAH isoforms by 96.1 ± 2.1 % and does not affect cell viability (Fig 3C;[4] ).
VEGF expression is increased in DDAH II over-expressing cells
VEGF stimulates the formation of tube-like structures by ECV304 and other cell types [10;11] . To determine whether VEGF might be involved in the effects of DDAH over-expression we assessed expression of VEGF. Northern blotting of 
Effect of a VEGF receptor antagonist on tube formation assays
DDAH over-expression increases VEGF expression and is associated with the enhanced formation of "tube-like" structures. Treatment of ECV304 with VEGF (10 µg l -1 ) increased tube formation by 161.2 ± 18.6 %. To determine whether the increased tube formation observed by DDAH II over-expression could be reduced by interfering with VEGF signalling we used oxindole-1, which competes for the ATP binding site on flk-1 [17] . In this series of experiments tube formation in DDAH overexpressing cells was 193.3 ± 24.0% greater than in untransfected ECV304 cells.
Addition of oxindole-1 (10 µM) reduced the area of tubes formed by over-expressing and wild type cells by 57.7 ± 11.3% and 60.8 ± 7.8 % respectively (Fig 5 A & B) . In the presence of oxindole-1, tube formation did not differ between ECV304 wild type and DDAH over-expressing cells. Northern blotting revealed levels of VEGF mRNA were significantly higher in the DDAH II over-expressing cells compared to the untransfected ECV304 cells, where n=3, levels of mRNA were corrected against differences in β-actin mRNA expression. 
